|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
US12702658B2
(en)
|
2020-04-24 |
2026-08-11 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
|
|
WO2021247859A1
(en)
*
|
2020-06-03 |
2021-12-09 |
Yumanity Therapeutics, Inc. |
Pyridopyrimidines and methods of their use
|
|
WO2022109487A1
(en)
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
AU2022281749A1
(en)
*
|
2021-05-24 |
2023-11-30 |
280 Bio, Inc. |
Nitrogen-containing heterocyclic compound, method for preparing same and use of same
|
|
WO2023018812A1
(en)
*
|
2021-08-10 |
2023-02-16 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
US20240417412A1
(en)
*
|
2021-08-10 |
2024-12-19 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
JP2024532735A
(ja)
*
|
2021-08-10 |
2024-09-10 |
アムジエン・インコーポレーテツド |
複素環式化合物及び使用方法
|
|
WO2023020519A1
(en)
*
|
2021-08-18 |
2023-02-23 |
Jacobio Pharmaceuticals Co., Ltd. |
1, 4-oxazepane derivatives and uses thereof
|
|
WO2023061294A1
(zh)
*
|
2021-10-13 |
2023-04-20 |
再鼎医药(上海)有限公司 |
含氮杂环类衍生物调节剂、其制备方法及应用
|
|
KR20240114793A
(ko)
|
2021-11-05 |
2024-07-24 |
프론티어 메디슨즈 코포레이션 |
Kras g12c 억제제
|
|
US20260200925A1
(en)
*
|
2021-11-24 |
2026-07-16 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras mutated proteins
|
|
WO2023107592A1
(en)
*
|
2021-12-08 |
2023-06-15 |
Kineta, Inc. |
Pyridopyrimidines and methods of their use
|
|
WO2023138583A1
(zh)
*
|
2022-01-21 |
2023-07-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
JP2025510656A
(ja)
*
|
2022-03-24 |
2025-04-15 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
複素環式化合物、その組成物、及びそれらを用いた治療方法
|
|
WO2023213269A1
(en)
*
|
2022-05-06 |
2023-11-09 |
Zai Lab (Shanghai) Co., Ltd. |
Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
|
|
WO2023246777A1
(en)
*
|
2022-06-20 |
2023-12-28 |
Jacobio Pharmaceuticals Co., Ltd. |
K-ras mutant protein inhibitors
|
|
WO2024008068A1
(en)
*
|
2022-07-04 |
2024-01-11 |
Jacobio Pharmaceuticals Co., Ltd. |
K-ras mutant protein inhibitors
|
|
CN116969977B
(zh)
*
|
2022-07-13 |
2026-05-01 |
重庆华森英诺生物科技有限公司 |
Pan-kras抑制剂
|
|
TW202426451A
(zh)
*
|
2022-08-24 |
2024-07-01 |
大陸商泰勵生物科技(上海)有限公司 |
具有抗kras突變腫瘤活性的化合物
|
|
WO2024083246A1
(en)
*
|
2022-10-21 |
2024-04-25 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Kras inhibitors
|
|
KR20250109197A
(ko)
|
2022-11-21 |
2025-07-16 |
트리라인 바이오사이언시스, 인크. |
스피로환식 디하이드로피라노피리미딘 KRas 억제제
|
|
CN118165011A
(zh)
*
|
2022-12-08 |
2024-06-11 |
润佳(上海)医药工程有限公司 |
Kras抑制剂及其用途
|
|
TW202430182A
(zh)
*
|
2022-12-14 |
2024-08-01 |
大陸商上海科州藥物研發有限公司 |
作為kras抑制劑的雜環化合物,及其製備和治療用途
|
|
US20260207615A1
(en)
*
|
2022-12-23 |
2026-07-23 |
Frontier Medicines Corporation |
Fluoropyridopyrimidine and fluoroquinazoline derivaties and methods of use thereof
|
|
CR20250413A
(es)
*
|
2023-04-05 |
2025-11-06 |
Pfizer |
Compuestos de pirido[4,3–d]pirimidina
|
|
AU2024272361A1
(en)
|
2023-05-12 |
2025-12-18 |
Jazz Pharmaceuticals Ireland Ltd. |
Pyrazolo[4,3-f]quinazoline derivatives as modulators of g12d mutant kras useful for the treatment of cancer
|
|
CN119101070A
(zh)
*
|
2023-06-07 |
2024-12-10 |
上海璎黎药业有限公司 |
一种含氮杂环化合物、其药物组合物及应用
|
|
WO2025006967A1
(en)
|
2023-06-30 |
2025-01-02 |
Bristol-Myers Squibb Company |
Kras inhibitors
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
KR20260054710A
(ko)
|
2023-08-17 |
2026-04-22 |
트리라인 바이오사이언시스, 인크. |
스피로시클릭 디히드로피라노피리미딘 KRas 저해제
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025064848A1
(en)
|
2023-09-21 |
2025-03-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyridine kras inhibitors
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
KR20260096846A
(ko)
|
2023-10-20 |
2026-06-24 |
머크 샤프 앤드 돔 엘엘씨 |
Kras 단백질의 소분자 억제제
|
|
WO2025163494A1
(en)
|
2024-01-29 |
2025-08-07 |
Jazz Pharmaceuticals Ireland Ltd. |
Condensed azines for the treatment of cancer
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025235740A1
(en)
*
|
2024-05-08 |
2025-11-13 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026119095A1
(zh)
*
|
2024-12-05 |
2026-06-11 |
上海璎黎药业有限公司 |
一种肼类结构化合物、其药物组合物及应用
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|